独一味胶囊治疗ⅢB型前列腺炎疗效分析

Efficacy of Lamiophlomis Rotata Capsule in the treatment of type ⅢB prostatitis

目的:探讨独一味胶囊治疗ⅢB型前列腺炎的疗效。方法:选择ⅢB型前列腺炎患者225例,随机分为两组:治疗组125例,口服独一味胶囊,一次3粒,一日3次,疗程4周;对照组100例,口服盐酸坦索罗辛缓释胶囊,0.2 mg/次,一日1次,疗程4周。以NIH-CPSI评分为疗效评价指标,比较治疗前后、停药4周后两组的疗效。结果:治疗组完成治疗120例,结果示:(1)治疗组治疗后疼痛症状评分、生活质量评分和总评分均较治疗前显著下降(5.30±1.23 vs 14.68±1.51;6.46±0.93 vs 8.52±1.05;17.50±2.77 vs 27.99±2.98)(P<0.05);而排尿症状评分治疗前后无明显改变(7.41±1.16 vs 7.16±1.04)(P>0.05)。(2)治疗组治疗后疼痛症状评分、生活质量评分和总评分均较对照组治疗后评分低(5.30±1.23 vs 13.67±1.49;6.46±0.93 vs 7.47±0.88;17.50±2.77 vs 25.77±2.01)(P<0.05);而排尿症状评分对照组较治疗组低(5.68±1.34 vs 7.16±1.04)(P<0.05)。(3)停药4周后,治疗组疼痛症状评分、生活质量评分和总评分,比治疗前仍显著下降(7.23±1.03 vs 14.68±1.51;6.58±0.87 vss 8.52±1.05;22.18±2.03 vs 27.99±2.98)(P<0.05);同时也明显低于对照组撤药后评分(7.23±1.03 vs 14.14±0.98;6.58±0.87 vs 8.12±0.72;22.18±2.03 vs 26.89±1.67)(P<0.05)。(4)治疗组因为头晕不适退出治疗2例,失联3例,其余患者未见明显不良事件发生。结论:独一味胶囊在改善ⅢB型前列腺炎患者疼痛症状及生活质量上安全、有效,有临床应用价值。

Objective ： To study the therapeutic effect of Lamiophlomis Rotata Capsule （LRC） in the treatment of type m B prostatitis. Methods： We randomly divided 225 patients with type ⅢB prostatitis into an experimental group （ n = 125 ） and a control group （n = 120）, the former treated orally with LRC at 3 capsules tid while the latter with tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd, both for 4 weeks. We compared the therapeutic effects between the two groups of patients based on the National Institutes of Health Chronic Prostatitis Symptom Index （NIH-CPSI） obtained before, immediately after and at 4 weeks after medication. Results： A total of 120 patients completed the treatment in the experimental group, which showed remarkable decreases as compared with the baseline in the pain score （5.30 ± 1.23 vs 14.68 ± 1.51, P〈0.05）, quality of life （QoL） score （6.46v 0.93 vs 8.52 ± 1.05, P〈0.05） and total NIH-CPSI score （17.50 ± 2.77 vs 27.99 ±2.98, P〈0.05） after 4 weeks of treatment, but no sig- nificant change in the urination symptoms score （7.41 ± 1.16 vs 7.16 ± 1.04, P 〉 0.05 ）. The experimental group achieved even markedly lower scores than the controls in the pain symptom （5.30 ± 1.23 vs 13.67 ± 1.49, P〈0.05）, QoL （6.46 ±0.93 vs 7.47 ± 0.88, P 〈0.05） and total NIH-CPSI （ 17.50 ± 2.77 vs 25.77 ± 2. 01, P 〈 0.05） but a higher urination symptoms score than the latter after medication （7.16 ± 1.04 vs 5.68 ± 1.34, P 〈 0.05 ）. At 4 weeks after drug withdrawal, the experimental groupalso showed significantly lower scores of the pain symptom （7.23 ± 1.03）, QoL （6.58 ± 0.87） and total NIH-CPSI （22. 18 ± 2.03 ） than the baseline （ all P 〈 0.05） and those in the control group （ 14.14 ± 0.98, 8.12 ± 0.72 and 26.89 ± 1.67） （ all P 〈 0.05 ）. Apart from dizziness in 2 of the patients, who gave up medication halfway, no other obvious adverse reactions were observed during the experiment. Conclusion ： Lamiophlomis Rotata Capsule deserves to be recommended for the treatment of type Ⅲ B prostati- tis for its safety and effectiveness in reducing the pain and improving the life quality of the patients.